Novo Nordisk Option Alert: Sep, 2026 $50 Puts at the Ask: 1850 vs 2862 OI; Earnings 11/5 Before Open [est] 

Novo Nordisk Option Alert: Sep, 2026 $50 Puts at the Ask: 1850 @ $5.24 vs 2862 OI; Earnings 11/5 Before Open [est] Ref=$58.665

Novo Nordisk Option Alert: Dec, 2027 $75 Calls at the Bid: 500 vs 1497 OI; Earnings 11/5 Before Open [est] 

Novo Nordisk Option Alert: Dec, 2027 $75 Calls at the Bid: 500 @ $11.15 vs 1497 OI; Earnings 11/5 Before Open [est] Ref=$59.205

Novo Nordisk

NOVO-NORDISK A/S-SPONS ADR

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Krasnoyarsk,,Russia,-,April,29,,2021:,Pfizer,Vaccine,Vial,With

Large Cap

News

Health Care

Invesco Managed Futures Strategy ETF Invesco International Growth Focus ETF

MTRA

MTSR

La società farmaceutica si prepara a una mossa che potrebbe rilanciare i suoi orizzonti nel settore dei farmaci per perdere peso.

Pfizer punta su un farmaco dimagrante per competere con Eli Lilly e Novo Nordisk

Valparaiso,,In,Usa,December,13,,2023:,Ozempic,Pen,And,Box

Biotech

Long Ideas

Trading Ideas

General

Questo fenomeno sta ridefinendo il concetto di benessere, attirando l&#39;attenzione di celebrità e investitori con prospettive da capogiro.

Ecco perché tutti adorano questo farmaco per perdere peso

Wegovy

Movers

Dati dal Congresso ESC mettono in luce un&#39;importante differenza tra due farmaci chiave per la gestione del rischio cardiometabolico.

Rischio di attacco cardiaco, ictus e morte: Wegovy supera Tirzepatide

Novo Nordisk AS

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Precidian ETFs Trust Novo Nordisk A/S B Shares ADRhedged

Novo Resources Corp Warrants (27/08/2023)

Press Releases

Deadline Soon: Novo Nordisk A/S (NVO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Legal

Portnoy Law Firm Announces Class Action on Behalf of Novo Nordisk A/S Investors

NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors With Losses in Excess of $100k to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO

Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join – Contact The Gross Law Firm

NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

DEADLINE ALERT for NVO and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm

Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit – NVO

LINE

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Merck & Co

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Viatris

Zoetis

HSBC

Morgan Stanley

TD Cowen

BMO Capital

Cantor Fitzgerald

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
11:28 AMOct 09, 2025	PUT	$50.00	Sep 18, 2026	342	1850	1850	65	2862	TRADE	BEARISH
10:19 AMOct 07, 2025	CALL	$75.00	Dec 17, 2027	797	500	500	33	1497	TRADE	BEARISH

Comments

Novo Nordisk

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO